[Immunoblastic lymphoma and liver cirrhosis]

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Leukemia·2016

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Leukemia·2016

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Leukemia·2016

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Leukemia·2015

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Leukemia·2015

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Leukemia·2014

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Haematologica·2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Haematologica·2026

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Haematologica·2026

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Haematologica·2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Haematologica·2026

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Haematologica·2026

Up-regulation of the kinase LRRK2, in enteric glia contributes to mucosal barrier impairment in Parkinson's disease via secretory autophagy.

British journal of pharmacology·2026

Mistakes in the management of irritable bowel syndrome-diarrhoeal subtype and mimics: a narrative review.

Current medical research and opinion·2026

Kikuchi-Fujimoto Disease - A Case Report in a Middle-aged Adult.

Annals of African medicine·2026

The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.

Inflammatory bowel diseases·2026

Association between body composition and perimenopausal symptom severity in Irish women.

Post reproductive health·2026

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications.

Immunology·2026

Related Experiment Videos

[Immunoblastic lymphoma and liver cirrhosis]

Related Concept Videos

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Up-regulation of the kinase LRRK2, in enteric glia contributes to mucosal barrier impairment in Parkinson's disease via secretory autophagy.

Mistakes in the management of irritable bowel syndrome-diarrhoeal subtype and mimics: a narrative review.

Kikuchi-Fujimoto Disease - A Case Report in a Middle-aged Adult.

The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.

Association between body composition and perimenopausal symptom severity in Irish women.

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications.

Related Experiment Videos

[Immunoblastic lymphoma and liver cirrhosis]

Related Concept Videos

Related Articles